Alligator Bioscience announces publication of biomarker data from OPTIMIZE-1 in Cell Reports Medicine supporting mitazalimab and mFOLFIRINOX in metastatic pancreatic cancer. Read more.
Bio Works Technologies reports great interest in WorkBeads affimAb Edge, the next generation Protein A resin for antibody purification. Read more.
Corline Biomedical is carrying out a directed issue of SEK 23 million. Read more.
Elekta publishes a new impact report that highlights the role of radiotherapy in cancer care. Read more.
ExpreS2ion Biotechnologies announces that the VICI-Disease Consortium has completed Nipah vaccine antigen and initiated the production phase. Read more.
Intellego Technologies clarifies press release regarding subsidiary Yuvio's order worth EUR 22 million. Read more.
Medivir decides on a fully guaranteed rights issue corresponding to approximately SEK 151 million. Read more.
NanoEcho improves the user interface for increased clinical usability. Read more.
QUIA PHARMA divests subsidiaries, raises financing of SEK 3 million and calls a general meeting to elect a board of directors. Read more.
Senzime launches EMGINE – next generation software for advanced neuromuscular monitoring. Read more.
SpectraCure receives final approval from the German authority to start clinical study. Read more.
ViroGates announces that suPAR Remedy makes a public takeover offer to shareholders at a 40 percent premium. Read more.
Xspray Pharma, portfolio company to Flerie, provides an update on the FDA process for Dasynoc where approval is delayed following objections from the contract manufacturer. Read more.
Zelluna receives positive feedback from MHRA and strengthens its clinical strategy in the UK for ZI-MA4-1, paving the way for first-in-human studies in the country. Read more.
Insider trading & whistleblowing
Invitations & presentations
C ROW Hansa Biopharma SOBI Xspray Pharma
Summons
Nomination committees
The latest from BioStock
» Watch Diamyd Medical's live broadcast at BioStock
» Order book grows for SenzaGen
» Lead Biologics publishes groundbreaking study in Nature Cancer
» AdjuTec Pharma’s CEO: “We must restore antibiotics”
» SynAct Pharma: "We're on track and on time"
» Alzinova comments on the FDA Fast Track Designation